Navigation Links
Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance
Date:4/26/2011

CARY, N.C., April 26, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of James "Jay" Dixon to Senior Vice President, Quality and Compliance. Dixon has spent more than 25 years in the pharmaceutical, biotechnology and CRO industries, and will bring his extensive experience to support Cetero's objective of maintaining its market leadership position.

(Photo:  http://photos.prnewswire.com/prnh/20110426/PH89541 )

At Cetero, Dixon will lead the Quality and Compliance team, ensuring that Cetero's unwavering commitment to quality provides its clients with the most dependable and accurate results.

"We are thrilled to have someone of Jay's caliber joining the Cetero team," said CEO Troy W. McCall, Ph.D. "Cetero considers quality and compliance to be the utmost priority. Jay's qualifications and background will undoubtedly help raise Cetero's benchmark for quality to an unprecedented new level."

Dixon's career has focused on clinical (GCP), preclinical (GLP), manufacturing (GMP) quality, medical operations and analytical chemistry. Dixon most recently led the quality and compliance efforts for MedImmune, LLC, as Vice President of GxP Quality Compliance. Prior to that, he was at Covance Central Laboratory Services as Vice President of Global Quality Assurance and Business Process Improvement – Six Sigma.

"Quality, safety and consistency are more important than ever in our industry," Dixon said. "I am committed to building upon Cetero's reputation as the leader in early-stage clinical research and to further improving on our record of high-quality performance and reliability."

Prior to his work at Covance, Dixon also held quality-focused leadership positions at Abbott Laboratories, Inc., Triangle Pharmaceuticals (now Gilead Sciences),
'/>"/>

SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cetero Research Leads Industry in Human Allergy Models
2. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
3. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
4. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
5. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Therapeutics,(Amex: CXM ) and its operating ... from a preclinical study, demonstrating a new ... for the potential,treatment of acute myocardial infarction ... Central (BMC) Cardiovascular Disorders (2008, 8:7, April,10, ...
... Regimen Designed to Avoid Risk of Toxicity ... Associated with Nucleoside Class of HIV Drugs, ... ) today announced that it has initiated a Phase ... in first-line therapy of adult treatment-naive HIV-infected patients,with R5-type ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 2Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 3Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 4Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 5Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 6
(Date:8/20/2014)... By Barbara Bronson Gray ... News) -- Although it,s extremely rare, colds, flu and ... of elevated risk for stroke in children, a new study ... have a stroke in the United States, said Dr. Heather ... neurology and pediatrics at the University of California, San Francisco ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... long been an option, but a new study shows that ... most common reasons women didn,t undergo reconstruction was that they ... or they were focused on their cancer treatment," said lead ... Sloan Kettering Cancer Center, in New York City. Also ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... treating cancer - using Botox. A study presented in ... shows that cancer growth could be suppressed by ... to cancer stem cells. The approach thus treated the ... safe and efficient. The researchers have thus far tested ... on humans. , The nervous system is crucial in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... University of Pittsburgh School of Medicine. , ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... July 10 Life is unfair, the economy is out ... true these statements might be, your ability to bounce back ... In his refreshing new self-help book, "Controlling Your Future: Six ... ), Richard Norgaard shows readers how to achieve total ...
... , , , , MARIETTA, Ga., July ... business executives that the top healthcare cost drivers for employers ... online webinar, hosted by Source Media, showed that lost workplace ... costly to employers. The purpose of the webinar was to ...
... Recently, students attended ... Anatomy 200 module of their Massage Therapy program at CNI College prepared them for a ... focus in this module. , ... Orange, CA (PRWEB) July 10, 2009 -- Recently, students attended a lab at a local ...
... ... can keep playing after shoulder joint replacement , ... Keystone, CO (Vocus) July 10, 2009 -- Replacing a joint in any ... not being able to return to a sport or activity. However, a new study presented ...
... A ... Hospital. , ... 2009 -- A Washington County woman is recovering well today after undergoing a new, robot-assisted ... is one of just a handful of bariatric patients in the region to benefit from ...
... July 9 Amgen (Nasdaq: AMGN ) announced ... Henderson, Ph.D., to the Company,s Board. Dr. Henderson, 48, ... School , having been the Eastman Kodak LFM Professor of ... MIT ) Sloan School since 1999. She specializes in technology ...
Cached Medicine News:Health News:'Controlling Your Future: Six Steps To A Better Life': New Self-Help Book Teaches the Art of Self-discipline, Self-control 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 2Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 3Health News:Poll of Business Executives Shows Most Companies Not Aware of True Costs of Healthcare 4Health News:CNI College Massage Therapy Students Experience Plastination & Cadaver Lab 2Health News:Shoulder Surgery Doesn't Prevent Return to Sports, According to New Study presented at AOSSM Annual Meeting 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 2Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 3Health News:Canonsburg Woman Undergoes Robot-Assisted Weight Loss Procedure at AGH 4Health News:Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors 2
Black elastomer. Smooth finish. Non-Sterile....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: